Microbiome

The microbiome
#CHMP #European Medicines Agency #MaaT Pharma #Microbiome

CHMP raises concerns about microbiome therapy for GvHD

MaaT Pharma has received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) for MaaT013 (Xervyteg) following re-examination for its conditional marketing authorisation application.  The committee’s concerns relate primarily to the attribution of clinical benefit and safety in the absence of a… Read More

#News #Regulatory

Gut microbiome
#Gut microbiome #Immunology #Microbiome #Neurodegenerative disorders

Driving drug discovery beyond the microbiome

Jeff Fischer, MBA, president of Longhorn Vaccines and Diagnostics, examines how upstream activations in the gut microbiome can be utilised to tackle therapeutic targets.  The microbiome has become a catch‑all explanation for everything from obesity to depression, but it can obscure a simpler and more actionable idea: that living microbes matter, but what they shed matters too. Every… Read More

#Exclusive Content

Microbiome
#Clinical trials #Drug discovery #Irritable Bowel Syndrome #Microbiome

EnteroBiotix announces positive results for IBS microbiome therapy  

Biopharmaceutical company EnteroBiotix has announced positive final results from its  TrIuMPH clinical trial, which is evaluating the company’s full-spectrum microbiome therapeutic for patients with irritable bowel syndrome with constipation (IBS-C) with constipation or diarrhoea (IBS-D).  The Phase IIa clinical trial included 122 UK patients and results show that EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score (IBS-SSS) versus placebo. Read More

#News

Gut microbiome
#Drug delivery #Gut microbiome #Microbiome #Nanoparticles #Painkillers

New microbiome and nanoparticle research could help treat gut pain

Recent discoveries into gut bacteria and nanomedicines could pave the way for better treatments of gut pain, new research suggests.  According to studies published in Cell Host & Microbe and Proceedings of the National Academy of Sciences (PNAS), scientists have discovered a new… Read More

#News

#Biotherapeutics #DNA #Drug discovery #Gut microbiome #Microbiome #Precision medicine #Synthetic biology #Synthetic DNA

Podcast: How is precision medicine making its mark in drug discovery?

This is the latest episode of the free DDW narrated podcast, titled “How is precision medicine making its mark in drug discovery?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA”… Read More

#News

The microbiome
#Gut microbiome #Microbiome #Microbiotica #Preclinical development #Ulcerative colitis (UC)

Preclinical data reveals mechanism behind microbiome therapy

Microbiotica has revealed new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC).   The data were shared at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February in Banff, Canada and at the European… Read More

#News

The microbiome
#Gut microbiome #Mental health #Microbiome #Psychiatry

Can the gut microbiome unlock new therapeutics in mental health?

Janet Sasso and Rumiana Tenchov, Information Scientists at CAS, discuss the relationship between the gut microbiome and mental health, reporting on topics that CAS has explored over the recent years. The gut-brain axis (GBA), a signalling pathway connecting the gastrointestinal tract and the central nervous system, has increasingly been found… Read More

#Exclusive Content

Microbiome
#Drug development #Drug discovery #Mental health #Microbiome #Oncology

Hot off the press: Read the Fall issue of DDW now

The DDW Fall issue is out now and asks if the gut microbiome can unlock new therapeutics for mental health disorders, places a spotlight on oncology and includes a market report on the North American drug discovery hotspots. It also features an exclusive guide on… Read More

#Editor's Choice #News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

New DDW Highlights podcast: 4 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The selected news highlights this week report breakthrough findings from early phase research and… Read More

#News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

This week in drug discovery (27-31 May) 

News round-up for 27-31 May by DDW Senior Digital Content Editor Diana Spencer. The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology… Read More

#News

The microbiome
#Biomica #Gut microbiome #Microbiome #Oncology #Phase I trial

Microbiome therapeutic shows potential in refractory cancers

Biomica has revealed encouraging initial findings from an ongoing Phase I clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with an anti-PD1 immune checkpoint inhibitor. The trial is assessing the drug in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell… Read More

#Cancer Research #Editor's Choice #News

Microbiome
#Microbiome #National Cancer Institute #National Institutes of Health (NIH) #Oncology #The Francis Crick Institute #vitamin D

Vitamin D boosts ‘good’ bacteria and improves immunity to cancer

Researchers have found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer. The researchers from the Francis Crick Institute, the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) and Aalborg University in… Read More

#Cancer Research #News #Trending News

Gut microbiome
#EnteroBiotix #Gut microbiome #Irritable Bowel Syndrome #Microbiome #Phase II trial

Microbiome drug to be tested in IBS clinical trial

EnteroBiotix, a Glasgow, UK based biotechnology company, has dosed the first patient in a clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS). The Phase II study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol… Read More

#News

#Clinical Microbiomics #DNASense #Mergers and acquisitions #Microbiome #RNA sequencing

Clinical Microbiomics makes third acquisition in 18 months

Clinical Microbiomics has acquired DNASense, a Danish microbiome clinical research organisation (CRO) specialised in long-read DNA and RNA sequencing technologies and bioinformatics. The acquisition adds long-read DNA and RNA sequencing technologies to Clinical Microbiomics’ multi-omics technologies for the microbiome field. H Bjørn Nielsen, CSO… Read More

#Business & Investment #News

Bacteria
#Biomica #Cancer research #Immuno-oncology #Microbiome #Oncology #Phase I trial

Results for microbiome-based cancer drug expected H1 2024

Biomica has completed enrolment in its Phase I trial evaluating the safety and tolerability of its microbiome-based immuno-oncology drug, BMC128. Initiated in July 2022, the Phase I trial was designed to evaluate BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small… Read More

#Cancer Research #News